Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
Wayne Kuznar
NCCN
,
Leukemia
,
Lymphoma
,
NCCN 2023 Conference Highlights
,
Hematologic Malignancies
June 2023, Vol 14, No 3 - Online Only
In a session during the 2023 National Comprehensive Cancer Network (NCCN) Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including
IGHV
gene status, 17p deletion/
TP53
mutation status, age, patient comorbidities, and resistance mutations.
Read More
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
Wayne Kuznar
NCCN
,
NCCN 2023 Conference Highlights
,
Renal-Cell Carcinoma
,
Genitourinary Cancers
June 2023, Vol 14, No 3 - Online Only
Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors.
Read More
Immunotherapy After Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer
By
Sharon Reynolds
Bladder Cancer
,
Immunotherapy
June 2023, Vol 14, No 3 - Online Only
Updated results from a large clinical trial confirm that, for some patients with bladder cancer that can be removed with surgery, receiving immunotherapy immediately afterwards is an effective treatment.
Read More
Biomarker Testing Helps Tailor Cancer Treatment, Improve Outcomes, Says New CancerCare Survey
Biomarkers
June 2023, Vol 14, No 3 - Online Only
Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. According to a new survey released by Cancer
Care
, a leading national cancer support organization, biomarker testing helped physicians tailor therapy for nearly all the respondent patients (93%) whose cancers were tested over the past 3 years.
Read More
Financial Navigation Can Reduce the Financial Toxicity of Cancer Care
By
Carmen Phillips
Financial Toxicity
June 2023, Vol 14, No 3 - Online Only
Results from a new study add to the evidence that programs aimed at reducing the financial burden of cancer treatment can save money and improve the quality of life of people with cancer and their loved ones.
Read More
Study Shows Health Insurance Status Mediates Racial and Ethnic Inequities in Advanced-Stage Cervical Cancer
Disparities in Cancer Care
,
Cervical Cancer
,
Gynecologic Cancer
June 2023, Vol 14, No 3 - Online Only
Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study.
Read More
New Subgroup Analysis Confirms Efficacy and Safety of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
By
Anne Rowe
ASCO GU 2023 HIGHLIGHTS
,
Prostate Cancer
,
Genitourinary Cancers
April 2023, Vol 14, No 2
An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease and should be considered the new standard of care for this patient population.
Read More
Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma
April 2023, Vol 14, No 2
First-line standard of care for patients with advanced cholangiocarcinoma has evolved from a chemotherapy-only regimen with gemcitabine/cisplatin to include the immune checkpoint inhibitor durvalumab based on results from TOPAZ-1 showing that the addition of durvalumab improved progression-free survival and overall survival compared with GemCis alone.
Read More
Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions
Value-Based Care
April 2023, Vol 14, No 2
The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills.
Read More
Zynyz Receives FDA Accelerated Approval for Merkel-Cell Carcinoma
FDA Approvals, News & Updates
,
Skin Cancer
April 2023, Vol 14, No 2
On
March 22, 2023
, the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz; Incyte Corporation), a programmed cell death 1–blocking antibody, for the treatment of adult patients with metastatic or recurrent locally advanced Merkel-cell carcinoma.
Read More
Page 7 of 338
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma